Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are highly heterogeneous and complicated by risk stratification and therapy selection. Artificial intelligence (AI) can examine large clinical, imaging, and pathological datasets to obtain more accurate survival predictions and support tailored treatment. Early results are promising but derive mainly from small, retrospective cohorts without robust external validation, with ethical issues still persisting. This video investigates current AI-based prognostic models in GEP-NENs, as well as their efficacy in predicting survival and optimizing patient management.